Full Title
A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)Purpose
Combining a personalized treatment called V940 and pembrolizumab immunotherapy may work well for people who had lung cancer surgery. The people in this study will have had presurgical chemotherapy and pembrolizumab followed by surgery before enrollment.
V940 is made in a laboratory. It uses genes in your cancer to teach your immune system to fight the cancer. V940 is given as an injection into a muscle. Pembrolizumab boosts the ability of the immune system to find and kill cancer cells. It is given intravenously (by vein).
If you join this study, you will be randomly assigned to get one of these treatments:
- V940 plus pembrolizumab
- Placebo (inactive drug) plus pembrolizumab
Who Can Join
To join this study, there are a few conditions. You must:
-
Have stage 2 or 3 NSCLC that was treated with presurgical chemotherapy and pembrolizumab, and then removed by surgery.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Jamie Chaft’s office at 646-608-3761.